Literature DB >> 29243169

Efficacy of two types of palliative sedation therapy defined using intervention protocols: proportional vs. deep sedation.

Kengo Imai1, Tatsuya Morita2, Naosuke Yokomichi3, Masanori Mori4, Akemi Shirado Naito3, Hiroaki Tsukuura3, Toshihiro Yamauchi3, Takashi Kawaguchi5, Kaori Fukuta6, Satoshi Inoue3.   

Abstract

PURPOSE: This study investigated the effect of two types of palliative sedation defined using intervention protocols: proportional and deep sedation.
METHODS: We retrospectively analyzed prospectively recorded data of consecutive cancer patients who received the continuous infusion of midazolam in a palliative care unit. Attending physicians chose the sedation protocol based on each patient's wish, symptom severity, prognosis, and refractoriness of suffering. The primary endpoint was a treatment goal achievement at 4 h: in proportional sedation, the achievement of symptom relief (Support Team Assessment Schedule (STAS) ≤ 1) and absence of agitation (modified Richmond Agitation-Sedation Scale (RASS) ≤ 0) and in deep sedation, the achievement of deep sedation (RASS ≤ - 4). Secondary endpoints included mean scores of STAS and RASS, deep sedation as a result, and adverse events.
RESULTS: Among 398 patients who died during the period, 32 received proportional and 18 received deep sedation. The treatment goal achievement rate was 68.8% (22/32, 95% confidence interval 52.7-84.9) in the proportional sedation group vs. 83.3% (15/18, 66.1-100) in the deep sedation group. STAS decreased from 3.8 to 0.8 with proportional sedation at 4 h vs. 3.7 to 0.3 with deep sedation; RASS decreased from + 1.2 to - 1.7 vs. + 1.4 to - 3.7, respectively. Deep sedation was needed as a result in 31.3% (10/32) of the proportional sedation group. No fatal events that were considered as probably or definitely related to the intervention occurred.
CONCLUSION: The two types of intervention protocol well reflected the treatment intention and expected outcomes. Further, large-scale cohort studies are promising.

Entities:  

Keywords:  Continuous infusion of midazolam; Deep sedation; Definition; Intervention protocol; Palliative sedation therapy; Proportional sedation

Mesh:

Substances:

Year:  2017        PMID: 29243169     DOI: 10.1007/s00520-017-4011-2

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  33 in total

1.  Development of a clinical guideline for palliative sedation therapy using the Delphi method.

Authors:  Tatsuya Morita; Seiji Bito; Yukie Kurihara; Yosuke Uchitomi
Journal:  J Palliat Med       Date:  2005-08       Impact factor: 2.947

2.  Reliability and validity of the Japanese version of the Support Team Assessment Schedule (STAS-J).

Authors:  Mitsunori Miyashita; Kazuko Matoba; Tomoyo Sasahara; Yoshiyuki Kizawa; Misae Maruguchi; Mayumi Abe; Masako Kawa; Yasuo Shima
Journal:  Palliat Support Care       Date:  2004-12

3.  Appropriateness and reliability testing of the modified Richmond Agitation-Sedation Scale in Spanish patients with advanced cancer.

Authors:  Miguel Angel Benítez-Rosario; Manuel Castillo-Padrós; Belen Garrido-Bernet; Toribio González-Guillermo; Luis Pedro Martínez-Castillo; Aceysele González
Journal:  J Pain Symptom Manage       Date:  2013-06       Impact factor: 3.612

Review 4.  Medication and monitoring in palliative sedation therapy: a systematic review and quality assessment of published guidelines.

Authors:  Eva Katharina Schildmann; Jan Schildmann; Isabel Kiesewetter
Journal:  J Pain Symptom Manage       Date:  2014-09-19       Impact factor: 3.612

Review 5.  Palliative sedation therapy in the last weeks of life: a literature review and recommendations for standards.

Authors:  Alexander de Graeff; Mervyn Dean
Journal:  J Palliat Med       Date:  2007-02       Impact factor: 2.947

6.  Trajectory of performance status and symptom scores for patients with cancer during the last six months of life.

Authors:  Hsien Seow; Lisa Barbera; Rinku Sutradhar; Doris Howell; Deborah Dudgeon; Clare Atzema; Ying Liu; Amna Husain; Jonathan Sussman; Craig Earle
Journal:  J Clin Oncol       Date:  2011-02-07       Impact factor: 44.544

7.  Midazolam therapeutic drug monitoring in intensive care sedation: a 5-year survey.

Authors:  Frank Bremer; Udo Reulbach; Helmut Schwilden; Jürgen Schüttler
Journal:  Ther Drug Monit       Date:  2004-12       Impact factor: 3.681

8.  Population pharmacokinetics of midazolam administered by target controlled infusion for sedation following coronary artery bypass grafting.

Authors:  K Zomorodi; A Donner; J Somma; J Barr; R Sladen; J Ramsay; E Geller; S L Shafer
Journal:  Anesthesiology       Date:  1998-12       Impact factor: 7.892

9.  Symptom Expression in the Last Seven Days of Life Among Cancer Patients Admitted to Acute Palliative Care Units.

Authors:  David Hui; Renata dos Santos; Gary B Chisholm; Eduardo Bruera
Journal:  J Pain Symptom Manage       Date:  2014-09-19       Impact factor: 3.612

10.  Using continuous sedation until death for cancer patients: a qualitative interview study of physicians' and nurses' practice in three European countries.

Authors:  Jane Seymour; Judith Rietjens; Sophie Bruinsma; Luc Deliens; Sigrid Sterckx; Freddy Mortier; Jayne Brown; Nigel Mathers; Agnes van der Heide
Journal:  Palliat Med       Date:  2014-07-25       Impact factor: 4.762

View more
  9 in total

1.  Palliative sedation in clinical scenarios: results of a modified Delphi study.

Authors:  M A Benítez-Rosario; T Morita
Journal:  Support Care Cancer       Date:  2018-08-10       Impact factor: 3.603

2.  Palliative sedation: beliefs and decision-making among Spanish palliative care physicians.

Authors:  Miguel Angel Benítez-Rosario; Belén Ascanio-León
Journal:  Support Care Cancer       Date:  2019-10-21       Impact factor: 3.603

Review 3.  Palliative Sedation for the Terminally Ill Patient.

Authors:  Ferdinando Garetto; Ferdinando Cancelli; Romina Rossi; Marco Maltoni
Journal:  CNS Drugs       Date:  2018-10       Impact factor: 5.749

4.  Identification and evaluation of observational measures for the assessment and/or monitoring of level of consciousness in adult palliative care patients: A systematic review for I-CAN-CARE.

Authors:  Anna-Maria Krooupa; Bella Vivat; Stephen McKeever; Elena Marcus; Joseph Sawyer; Paddy Stone
Journal:  Palliat Med       Date:  2019-08-22       Impact factor: 5.713

Review 5.  Unanswered questions and future direction in the management of terminal breathlessness in patients with cancer.

Authors:  Masanori Mori; Takashi Yamaguchi; Yoshinobu Matsuda; Kozue Suzuki; Hiroaki Watanabe; Ryo Matsunuma; Jun Kako; Kengo Imai; Yuko Usui; Yoshihisa Matsumoto; David Hui; David Currow; Tatsuya Morita
Journal:  ESMO Open       Date:  2020-09-30

Review 6.  How to measure the effects and potential adverse events of palliative sedation? An integrative review.

Authors:  Alazne Belar; María Arantzamendi; Sheila Payne; Nancy Preston; Maaike Rijpstra; Jeroen Hasselaar; Lukas Radbruch; Michael Vanderelst; Julie Ling; Carlos Centeno
Journal:  Palliat Med       Date:  2020-12-14       Impact factor: 4.762

7.  Defining "Continuous Deep Sedation" Using Treatment Protocol: A Proposal Article.

Authors:  Tatsuya Morita; Kengo Imai; Masanori Mori; Naosuke Yokomichi; Satoru Tsuneto
Journal:  Palliat Med Rep       Date:  2022-02-08

8.  Association of the RASS Score with Intensity of Symptoms, Discomfort, and Communication Capacity in Terminally Ill Cancer Patients Receiving Palliative Sedation: Is RASS an Appropriate Outcome Measure?

Authors:  Kengo Imai; Tatsuya Morita; Naosuke Yokomichi; Masanori Mori; Akemi Shirado Naito; Toshihiro Yamauchi; Hiroaki Tsukuura; Yu Uneno; Satoru Tsuneto; Satoshi Inoue
Journal:  Palliat Med Rep       Date:  2022-04-08

Review 9.  The Decision-Making Process for Palliative Sedation for Patients with Advanced Cancer-Analysis from a Systematic Review of Prospective Studies.

Authors:  Alazne Belar; Maria Arantzamendi; Johan Menten; Sheila Payne; Jeroen Hasselaar; Carlos Centeno
Journal:  Cancers (Basel)       Date:  2022-01-08       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.